Best of ASCO - 2014 Annual Meeting



Esophageal or Gastric Cancer

Gastrointestinal (Noncolorectal) Cancer

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
A multi-center, randomized, prospective study evaluating the optimal radiation dose of definitive concurrent chemoradiation for inoperable esophageal squamous cell carcinoma.

Yanjun Xu


A phase II study of apatinib on reversing resistance of paclitaxel-containing regimens in advanced gastric cancer (AGC).

Rongbo Lin


A phase II study of irinotecan as single agent in the third-line treatment of unresectable or metastatic gastric cancer.

Zhe Zhang


A phase II study of perioperative intraperitoneal paclitaxel plus S-1/paclitaxel for curatively resectable gastric cancer with serosal invasion: The GAPS study.

Seiji Ito


A randomized phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.

Kensei Yamaguchi


A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT).

Akitaka Makiyama


A randomized phase III study comparing S-1 plus docetaxel with S-1 alone as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer (JACCRO GC-07 trial).

Yasuhiro Kodera


A retrospective study of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of gastric cancer with synchronous peritoneal metastasis.

Bin Xiong


A single-arm confirmatory study of definitive chemoradiotherapy (dCRT) including salvage treatment in patients (pts) with clinical (c) stage II/III esophageal carcinoma (EC) (JCOG0909).

Yoshinori Ito


Adjuvant radio chemotherapy for gastric cancer: Is chemotherapy alone better than combined radio chemotherapy? Results of a meta-analysis.

Jan Haussmann


Adjuvant treatment in stage III gastric cancer patients in Brazil and Peru: Results of a retrospective study in two cancer centers in Latin America.

Jose Eduardo Nunez


An intergroup phase III trial of ramucirumab plus irinotecan in third or more line beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial).

Daisuke Sakai


An investigator initiated multicenter phase I/II study of paclitaxel, ramucirumab with nivolumab as the second-line treatment in patients with metastatic gastric cancer.

Tomohiro Nishina


Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction and gastric adenocarcinoma.

Ryosuke Okamura


Angiotensin system inhibitors during induction chemotherapy for esophageal adenocarcinoma: Analysis of survival.

Abraham Geller


Apatinib in patients with adenocarcinoma of stomach or gastroesophageal junction: A prospective, multicenter, non-interventional study (Ahead-G202).

Chunmei Bai


Apatinib plus SOX regimen as neoadjuvant chemotherapy for locally advanced gastric cancer: A phase II study.

Ya'nan Zheng


Association between Helicobacter pylori infection and outcome in advanced gastric cancer patients treated with S-1 adjuvant chemotherapy.

Satoshi Nishizuka


Biomarker study for trastuzumab continuation beyond progression in a randomized phase II trial of weekly paclitaxel±trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum (WJOG7112G).

Yasutaka Sukawa


BMI differences for clinical outcome in patients with advanced or metastatic gastric cancer treated with apatinib: Data from a post-marketing phase IV study (Ahead-G201).

Yu-Xian Bai


Can chemoradiotherapy improve survival after an R1 resection for gastric cancer: A retrospective study of a Chinese cohort.

Menglong Zhou


Capecitabine plus oxaliplatin versus capecitabine plus oxaliplatin with concurrent radiotherapy in the treatment of gastric cancer after D2 gastrectomy.

Congying Xie


Changes in bone metabolism after gastric cancer surgery: A prospective observational study.

Yosuke Atsumi


Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: Efficacy and safety in the phase III randomized factorial ASPECT trial.

Janusz Jankowski


Circulating tumor DNA dynamics in resectable gastric cancer.

Alessandro Leal


Clinical benefit of continuing apatinib beyond progression in advanced or metastatic gastric cancer.

Shukui Qin


Clinical efficacy and safety of apatinib combined with docetaxel in second-line treatment for advanced gastric cancer: A prospective study.

Mudan Yang


Clinical impact of nodal status on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with gastric peritoneal metastasis.

Pierre Emmanuel Bonnot


Clinical-pathological features in HER2-positive advanced gastric cancer: Italian data of the Reggio Emilia Clinical Cancer Centre.

Francesco Iachetta


Co-existing alterations in cell-cycle pathway genes and impact on benefit from trastuzumab in advanced esophagogastric cancers (EGC): Analysis of 527 Her2-amplified cases.

Joseph Chao


Comparison of bimodality versus trimodality therapy for esophageal or gastroesophageal junction (GEJ) cancer: Experience from the Princess Margaret Cancer Centre.

Akina Natori


Comparison of clinical outcome and safety after minimally invasive esophagectomy: Ivor Lewis versus McKeown—A real-world multicenter observational study from China.

Yang Liu


Complete preoperative chemotherapy regimen FLOT: Evaluating the safety and histopathologic results in gastric cancer (GC).

Luis Villanueva


Compliance with biweekly SOX combination chemotherapy versus triweekly SOX as a first-line therapy for elderly patients with advanced gastric cancer.

Shu Zhang


Comprehensive genomic profiling of gastric cancer to reveal distinctive genomic alterations between peritoneal metastasis (PM) patients (pts) and non-PM pts.

Rongbo Lin


Conversion therapy using S1/paclitaxel chemotherapy plus apatinib in unresectable gastric cancer: Updated data from a phase II trial.

Xiangdong Cheng


Cost-effectiveness of single versus dual immune checkpoint blockade for chemotherapy-refractory esophageal, GE junction, and gastric cancers.

Sassan Ostvar


Defective homologous recombination in platinum based chemotherapy for gastric cancer.

Hiroshi Ichikawa


Development of a prognostic index for gastric cancer with liver metastasis at the initial diagnosis: A single center retrospective study.

Yakun Wang


Development of non-hematological adverse events in apatinib-treated gastric cancer and their association with clinical outcome: Results from a phase IV study.

Yi Ba


Differential response to adjuvant chemotherapy based on Lauren subtype affects clinical outcome of gastric cancer: A cohort study and meta-analysis.

Kunning WANG


Diversity of first-line palliative systemic treatments for esophagogastric cancer patients with synchronous metastases: A real world evidence study.

Willemieke P.M. Dijksterhuis


Does hypertension history in patients with advanced gastric cancer has an impact on clinical outcomes following apatinib treatment? A subgroup analysis based on data from Ahead-G201 study.

Tienan Yi


Dynamic perspective of neutrophil-lymphocyte ratio in metastatic gastric cancer.

Antia Cousillas


Effect of ECOG PS on outcome of advanced or metastatic gastric patients treated with apatinib: Analysis from a post-marketing phase IV study.

Xiaoyan Lin


Effect of perioperative oral care on prevention of postoperative pneumonia associated with esophageal cancer surgery: A multicenter case-control study with propensity score matching analysis.

Sakiko Soutome


Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis.

Kohei Shitara


Efficacy and safety of apatinib with or without radiotherapy as second-line or beyond therapy in patients with advanced/recurrent esophageal squamous cell carcinoma.

Jiahua Lv


Efficacy and safety of chemotherapy DCX (DOCETAXEL–CISPLATIN–CAPECITABINE) as a perioperative treatment of gastric cancer: A single institution analysis.

Ismael Macias Declara


Enteral feeding during preoperative chemotherapy for patients with local advanced esophageal cancer: A feasibility study.

Takashi Ogata


Factors of local immunity in esophageal tumors of various stages.

Adlan Lechaevich Bazaev


Feasibility and clinical value of circulating tumor DNA testing in patients with gastroesophageal adenocarcinoma.

Madiha Iqbal


Feasibility study of trastuzumab (T) and pertuzumab (P) added to neoadjuvant chemoradiotherapy (nCRT) in resectable HER2+ esophageal adenocarcinoma (EAC) patients (pts): The TRAP study.

Sandor Schokker


FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in.

Daniel V.T. Catenacci


Final analysis of single-arm confirmatory study of diagnostic endoscopic resection(ER) plus selective chemoradiotherapy (CRT) for stage I esophageal squamous cell carcinoma (ESCC): JCOG0508.

Keiko Minashi


Final results of a phase 3 study of comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in chemoradiotherapy for locally advanced esophageal carcinoma (ESO-Shanghai 1).

Yun Chen


FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: The RAMIRIS study.

Sylvie Lorenzen


Fraction of diffuse gastric cancer attributable to dietary risk factors.

Marina Candido Visontai Cormedi


Frequency of overexpression of HER3 and prognostic consequences in European patients with early gastric cancer.

Nieves Martinez Lago


Health-related quality-of-life (HRQoL) results from the FAST study, a phase 2 trial of epirubicin, oxaliplatin and capecitabine with or without IMAB362 in patients with advanced CLDN18.2+ gastric (GA) and gastroesophageal junction (GEJ) adenocarcinoma.

Robert Morlock


Iconic: Peri-operative immuno-chemotherapy in operable oesophageal and gastric cancer.

Sonia Mansukhani


Immunomarker combined with clinical features to support vector machines classifier for prediction of gastric cancer survival and adjuvant chemotherapeutic benefits.

Tuanjie Li


Impact of adjuvant FOLFOX on quality of life and peripheral neuropathy incidence in patients with localized gastric cancer.

Sebastián Mondaca


Impact of time to progression on first-line therapy on clinical outcomes in advanced gastric cancer treated with apatinib: data from a phase IV study (Ahead-G201).

Zhong Xie


Incidence rate and clinic-pathologic features of EBV-associated gastric carcinoma in China.

Rui-hua Xu


Induction chemoradiotherapy for esophageal cancer: Comparing CROSS regimen with cisplatin/5-FU.

Abraham Geller


Induction nivolumab or nivolumab/ipilimumab prior to concurrent chemoradiation plus nivolumab in patients with operable stage II/III esophageal/gastroesophageal junction cancer.

Ronan Joseph Kelly


International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1).

Masanori Terashima


Investigation of PD-L1 expression and response to pembrolizumab (pembro) in gastric cancer (GC) and cervical cancer (CC) using combined positive score (CPS) and tumor proportion score (TPS).

Karina Kulangara


Is cytoreductive surgery and hyperthermic intraperitonealchemotherapy reasonable treatment for gastric signet-ring cell adenocarcinoma and linitis plastica with peritoneal metastasis? CYTO-CHIP study—Ancillary results.

Pierre Emmanuel Bonnot


Is esophagectomy indicated after induction therapy in patients with clinical N3 esophageal cancer?

Shadia Ibrahim Jalal


KEYNOTE-585: Phase 3 study of chemotherapy (chemo) + pembrolizumab (pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer.

Yung-Jue Bang


Laparoscopic sentinel node navigation surgery versus laparoscopic standard gastrectomy with lymph node dissection in early gastric cancer: Results of postoperative morbidity and mortality from a multicenter randomized controlled trial (SENORITA trial).

Keun Won Ryu


Laparoscopic versus open surgery for advanced gastric cancer.

Guoxin Li


Laparoscopy-assisted versus open D2 distal gastrectomy for advanced gastric cancer: Five year overall survival and morbidity results from a randomized phase II multicenter clinical trial (COACT 1001).

Young Woo Kim


Long-term outcomes in laparoscopic D2 gastrectomy for gastric cancer: A large comprehensive study proposing novel hypotheses.

Tuanjie Li


Long-term prognosis of α-fetoprotein-producing gastric cancer defined as immunohistochemichal expression.

Yukio Maezawa


Lymph node ratio as a clinical determinant for selecting adjuvant chemotherapy regimen in curative D2 resected gastric cancer.

Jun-Eul Hwang


Maintenance therapy with trastuzumab +/- fluoropyrimidine in non-progressive HER-2 positive advanced gastroesophageal cancer patients after first-line chemotherapy.

Anthony Lopez


Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).

Daniel V.T. Catenacci


MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer.

Do-Youn Oh


Multicenter observational study on re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab.

Tomomi Kashiwada


Multicenter phase II trial of pembrolizumab (pembro) in previously-treated metastatic esophageal cancer.

Peter C. Enzinger


NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Michael Cecchini


Outcomes for advanced HER2 positive gastroesophageal cancer by anatomical location: Experience from the Princess Margaret Cancer Centre.

Charles Henry Lim


Oxaliplatin plus capecitabine (XELOX) in the perioperative treatment of locally advanced gastric adenocarcinoma in combination with D2 gastrectomy (NEO-CLASSIC).

Tianshu Liu


Oxaliplatin, 5FU and nab-paclitaxel as neoadjuvant regimen in patients with resectable oesogastric adenocarcinoma: A GERCOR phase 2 study (FOXAGAST).

Sarah Sophie Watson


Paclitaxel combined with ramucirumab as the second-line chemotherapy for elderly patients with advanced gastric cancer.

Tetsuya Kusumoto


PD-L1 and IDO1 expression and clinical outcome in 305 patients with surgically resected esophageal cancer.

Yoshifumi Baba


Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.

Charles S. Fuchs


Pembrolizumab for patients with previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase 2 KEYNOTE-180 study.

Manish A. Shah


Personal visceral fat index (PVF index), a new predictive factor for chemotherapy efficacy in patients with advanced gastric cancer.

Xiaodong Zhu


PET scan-directed chemoradiation (CRT) for esophageal squamous cell carcinoma (ESCC): No benefit for salvage chemo in PET non-responders (PETnr).

Megan Greally


Phase III study comparing triplet chemotherapy with S-1 and cisplatin plus docetaxel versus doublet chemotherapy with S-1 and cisplatin for advanced gastric cancer (JCOG1013).

Yasuhide Yamada


Phase III study of intraperitoneal/intravenous adjuvant chemotherapy compared intravenous adjuvant chemotherapy in patients with stage III gastric cancer.

Yang Yang


Postradiation ctDNA status as a prognostic factor in locally advanced esophageal squamous cell carcinoma.

Ru Jia


Prediction of clinical outcomes for early gastric cancer using radiomic signatures derived from the quantitative texture analysis of conventional CT scans and machine learning.

Jacob G Woolsey


Preliminary result of phase 1/2 study of ramucirumab plus nivolumab in patients with previously treated advanced gastric adenocarcinoma (NivoRam study).

Daisuke Takahari


Prognostic factors associated with survival and recurrence in resectable gastric cancer: Retrospective analysis of 379 patients operated at Cremona Hospital from 2007 to 2016.

Michele Ghidini


Prognostic impact of PIK3CA mutation in esophageal cancer: Molecular profiling by next-generation sequencing using formalin-fixed, paraffin-embedded tissues.

Tomoya Yokota


Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in gastric cancer patients who underwent palliative chemotherapy.

Seok Yun Kang


Prognostic value of CEA mRNA in the peritoneal lavage of patients undergoing curative surgery for gastric cancer.

Yan Yang


Psychiatric comorbidities among esophageal cancer survivors in South Korea: A nationwide population-based, longitudinal study.

Jaesung Heo


Quality of life in the CRITICS study, a multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer.

Romy Van Amelsfoort


Racial disparities in surgical management and survival in hispanic patients with potentially resectable esophageal cancer.

Dave Gupta


Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer: Japan Clinical Oncology Group study (JCOG0501).

Yoshiaki Iwasaki


Randomized, double-blind, phase 2 study of S-1 plus oxaliplatin (SOX) with or without ramucirumab (RAM) as first-line therapy followed by paclitaxel plus RAM as second-line therapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma (AGC).

Kei Muro


Real-world first-line advanced gastric cancer in western and Asian countries: Treatment patterns and impact on quality of life (QOL).

Sun Young Rha


Real-world outcomes and patient (pt) characteristics for the second-line (2L) treatment of gastric, esophageal, or gastroesophageal junction (GEJ) adenocarcinoma (EGAC).

Afsaneh Barzi


Reconstruction of continuous isoperistaltic jejunum interposition after proximal gastrectomy preserving gastric antrum.

Xinbao Wang


Response to apatinib by the number of metastatic organs in patients with advanced or metastatic gastric cancer: Subgroup analysis from a phase IV study (Ahead-G201).

Yifu He


Response to immune checkpoint inhibitors in recurrent/metastatic esophageal squamous cell carcinoma may be affected by tumor site and lesion size.

Jhe-Cyuan Guo


Results from the safety interim analysis of the Adjuvant chemoRadioTherapy In Stomach Tumors 2 (ARTIST 2) randomized, multi-center clinical trial.

Se Hoon Park


Risk of second primary cancers among patients with stomach cancer: A population-based study in South Korea.

Jaesung Heo


Role of infiltrating CD8 lymphocytes, microsatellite instability and h. pylori level in gastric cancer.

Angela Leonardo


Role of neoadjuvant chemotherapy or chemoradiotherapy in oesophageal carcinoma.

Herui Yao


Role of volume reduction gastrectomy according to tumor location in patients with gastric cancer with a single non-curable factor: Supplementary analysis of REGATTA trial (JCOG0705/KGCA01).

Kazumasa Fujitani


Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers.

Antoine Hollebecque


Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal adenocarcinoma: Early results from Big Ten Cancer Research Consortium study.

Hirva Mamdani


Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.

Ronan Joseph Kelly


Safety of apatinib as third-line or beyond treatment in advanced or metastatic gastric cancer: Results from a multicenter phase IV study (Ahead-G201).

Jin Li


Safety, antitumor activity and biomarker of anti-PD-1 antibody in patients with advanced esophageal carcinoma.

Xiangrui Meng


Safety, pharmacokinetics and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer.

Jifang Gong


Selumetinib plus docetaxel as second-line chemotherapy in KRAS mutant, KRAS amplified or MEK signatured gastric cancer patients: First arm of the umbrella trial in GC though the molecular screening, VIKTORY trial.

Jeeyun Lee


Should combination chemotherapy be used in all advanced gastric cancer patients?

Mi Sun Ahn


Single-arm confirmatory trial of laparoscopy assisted total or proximal gastrectomy with nodal dissection for clinical stage I gastric cancer: Japan Clinical Oncology Group study JCOG1401.

Hitoshi Katai


Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.

Karyn A. Goodman


Survival outcomes in gastric and gastroesophageal junction adenocarcinoma treated with peri-operative chemotherapy with or without pre-operative radiotherapy.

Sibo Tian


Targeted-sequencing and comprehensive molecular profiling of gastric signet ring cell carcinoma.

Jia Wei


Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients.

Anthony Lopez


The activity of crizotinib in chemo-refractory MET-amplified esogastric adenocarcinomas: Results from the AcSé-crizotinib program.

Thomas Aparicio


The analysis of T cell subset and the expression of PD-L1, HLA in esophageal squamous cell carcinoma.

Tomoya Sudo


The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Manish A. Shah


The correlation of CT volumetry with prognosis in advanced gastric cancer treated with neoadjuvant chemotherapy.

Chao Chen


The efficacy and safety of apatinib in the treatment of chemotherapy-resistant alpha-fetoprotein positive gastric cancer.

Feng Wang


The mutational landscape of circulating cell free DNA in patients with esophageal squamous cell carcinoma response and non-response to neoadjuvant chemotherapy.

Ruixiang Zhang


The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced gastric cancer (GC).

Satoshi Yuki


Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.

Raghav Sundar


Translating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: Prevalence and outcome dataTranslating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: prevalence and outcome data.

Itziar Gardeazabal


Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, single-arm study.

Feng Wang


Treatment decision priorities and decisional support experiences of gastric cancer survivors.

Linda S. House


Tumor mutation burden (TMB) and immune-related adverse events (irAEs) compared to antibiotic (abx) use to predict for response to immune checkpoint inhibitors in esophagogastric cancer (EGC).

Megan Greally


Two novel registry-based prediction models for overall survival in patients with metastatic esophageal or gastric cancer.

Héctor van den Boorn


Understanding treatment, utilization, and costs in advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC): Implications for episodic payment models.

Ronan Joseph Kelly


Updated report of a randomized phase III trial comparing 4 and 8 courses of S-1 adjuvant chemotherapy for p-stage II gastric cancer: JCOG1104 (OPAS-1).

Masanori Terashima


What is the outcome of receiving subsequent therapy among patients (pts) with advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC)? Experience from electronic health records (EHR).

Dung T. Le